

[Home](#) > [BioCentury on BioBusiness](#) > [Emerging Companies](#) > Amyndas: Complement shutdown

## Amyndas developing super compstatins for complement-mediated disorders

### Amyndas: Complement shutdown

By Kai-Jye Lou  
Senior Writer

Published on Monday, February 10, 2014

Transatlantic sister companies [Amyndas Pharmaceuticals S.A.](#) and [Amyndas Pharmaceuticals LLC](#) are developing therapies to treat complement-mediated disorders that could be more potent than other complement inhibitors, potentially opening up new indications.

Lead candidate [Amanden](#) comes from a class of synthetic analogs of the peptidic complement 3 (C3) inhibitor [compstatin](#), which the company calls super compstatins.

*55 words displayed of 702 words total.*

To read this article, you must be an Archives subscriber. Please choose one of the options below.

#### Read the Rest of this Article

##### Current Subscribers

If you are a current subscriber, log in below or in the upper right corner of this page.

##### Purchase Options

- Purchase this article for individual use ⓘ \$85 USD
- Purchase this article for

##### Related tables, figures and sidebars

 [Sidebar: Corporate Profile](#)

-  [print](#)
-  [bookmark](#)
-  [archives search](#)
-  [email to colleague](#)
-  [tw eet this](#)

#### BCIQ Profiles Referenced

##### Organizations

[Alcon Inc.](#)  
[Alexion Pharmaceuticals Inc.](#)  
[Amyndas Pharmaceuticals LLC](#)  
[Amyndas Pharmaceuticals S.A.](#)  
[Apellis Pharmaceuticals Inc.](#)  
[National Institutes of Health](#)  
[Novartis AG](#)  
[Potentia Pharmaceuticals Inc.](#)  
[University of Pennsylvania](#)

##### Products

[Amanden](#)  
[APL-1](#)  
[compstatin](#)  
[POT-4](#)  
[Soliris](#)

##### Molecular Targets

[complement 3 \(C3\)](#)

#### Free Trial 4 Weeks of Access

Get a 4-week free trial subscription to see the important articles you are missing.

[Get 4 Weeks Free](#)